FindMyKOL
Clinical trialNCT06410300RecruitingObservational

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

NCT06410300 is an observational study sponsored by Bo Lu. As of 21 Nov 2026, it is recruiting participants. It studies Immunotherapy in Lung Cancer. The registry lists an enrollment of 125 participants at 3 sites in 1 country. The registry lists a start date of 19 Apr 2024 and a primary completion date of 19 Apr 2028. One of its registered investigators has a FindMyKOL profile.

SponsorBo Lu →Enrollment125Lung Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06410300
FieldValue
Registry IDNCT06410300
StatusRecruiting
Study typeObservational study
Lead sponsorBo Lu
Enrollment125
Registered sites3
Countries1
ConditionsLung Cancer
DrugsImmunotherapy
Start19 Apr 2024
Primary completion19 Apr 2028
Study completion19 Apr 2030
Last update posted30 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Missouri, United States1 site, 1 recruiting
  • University of Missouri - Ellis Fischel Cancer Center

    Columbia

    Bo Lu, MDGregory Biedermann, MDRuobing Xue, MD
    Recruiting
New Jersey, United States1 site, 1 recruiting
  • Rutgers Cancer Institute of New Jersey

    New Brunswick

    Salma Jabbour, MD
    Recruiting
New York, United States1 site, 1 recruiting
  • University of Rochester Medical Center

    Rochester

    Yuhchyau Chen, MD, PhD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 site, 1 recruitingNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew Jersey: 1 site, 1 recruitingNJ1ConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 site, 1 recruitingMO1KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Immunotherapy
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06410300

Each answer restates registry values shown on this page.

What is NCT06410300?

NCT06410300 is an observational study sponsored by Bo Lu. It studies Immunotherapy in Lung Cancer.

Is NCT06410300 recruiting?

As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.

Who leads NCT06410300?

The registry names Bo Lu, MD (principal investigator, Chair, Department of Radiation Oncology) as the overall official.

Where does NCT06410300 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06410300 study?

The registered drug and biological interventions are Immunotherapy.

When is NCT06410300 expected to complete?

The registry lists a primary completion date of 19 Apr 2028 and a study completion date of 19 Apr 2030. The sponsor last updated the record on 30 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.